Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
somatropine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| somatropine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| somatropine | DRUG | subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg |
Inclusion Criteria: * Children over 3 years of age with growth hormone deficiency, requiring treatment with MAXOMAT® according to the criteria of the MA. Exclusion Criteria: * The above information is not intended to contain all considerations relevant to a patient's potential participation in a ...
Somatropine is used for Growth Hormone Deficiency. It is an endocrine therapy developed by Sanofi and is in Phase 3 clinical development. It is a small molecule rather than a recombinant protein product.
Somatropine targets GHR, the growth hormone receptor, and acts as an agonist at that receptor. Agonist activity at GHR is the mechanism by which the drug is intended to address Growth Hormone Deficiency.
Somatropine is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor associated with the clinical development program for this Growth Hormone Deficiency candidate.
Somatropine is in Phase 3 clinical development for Growth Hormone Deficiency. It is an investigational agent and is not described as approved. Its development is led by Sanofi.
Somatropine has been studied in one completed Phase 3 trial, NCT00476385, titled Practicability and Acceptability of Stylomax in Children. That trial enrolled 12 participants in France, included children aged 3 years and older, and was uncontrolled and not randomized.
Somatropine is associated with the name Stylomax, which appears in the title of its Phase 3 trial in children with Growth Hormone Deficiency. Readers searching for Stylomax are looking at the same development program as somatropine.